Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials

References

• Younossi Z, Koenig A, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al., Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6): 2672–2682.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine J, et al., The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1): 328–357.
   PubMed Web of Science ®Google Scholar
• Dulai P, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• Huang D, El-Serag H, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Clin Pract Gastroenterol Hepatol. 2021;18(4):223–238.
   Google Scholar
• Targher G, Tilg H, Byrne C. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–588.
   PubMed Web of Science ®Google Scholar
• Negi CK, Babica P, Bajard L, et al. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022 Jan;126:154925.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Balsano C, Santini SJ, et al. It is high time physicians thought of natural products for alleviating nafld is there sufficient evidence to use them? Int J Mol Sci. 2021 Dec 14;22:24.
   Web of Science ®Google Scholar
• Blond E, Disse E, Cuerq C, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia. 2017;60(7):1218–1222.
   PubMed Web of Science ®Google Scholar
• Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–315.
   PubMed Web of Science ®Google Scholar
• Violi F, Cangemi R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;363(12):1185–1186. author reply 1186.
   PubMedGoogle Scholar
• Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30(9):1026–1032.
   PubMed Web of Science ®Google Scholar
• Davidson M, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018;135:102–110.
   PubMed Web of Science ®Google Scholar
• Li Z, Sun M, Wang F, et al. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis. Int J Clin Pharmacol Ther. 2017;55(3):210–219.
   PubMed Web of Science ®Google Scholar
• Klein E, Thompson I, Tangen C, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–1556.
   PubMed Web of Science ®Google Scholar
• Fu Z, Cai X, Yang W, et al. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes. 2021;12(1):84–97.
   PubMed Web of Science ®Google Scholar
• Kumar J, Memon R, Shahid I, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53(1):44–51.
   PubMedGoogle Scholar
• Ghosh-Swaby O, Goodman S, Leiter L, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8(5):418–435.
   PubMed Web of Science ®Google Scholar
• Dong Y, Lv Q, Li S, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(3):284–295.
   PubMed Web of Science ®Google Scholar
• Borodavkin P, Sheridan W, Coelho C, et al. Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Obes Metab. 2022;24(2):337–342.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL),European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed). 2009;339(jul21 1):b2700.
   PubMed Web of Science ®Google Scholar
• Higgins J, Altman D, Gøtzsche P, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2011;343(oct18 2):d5928.
   PubMed Web of Science ®Google Scholar
• Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13(1):35.
   PubMedGoogle Scholar
• Dias S, Welton N, Caldwell D, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7–8):932–944.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades A, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171.
   PubMed Web of Science ®Google Scholar
• Chaimani A, Higgins J, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PloS one. 2013;8(10):e76654.
   PubMed Web of Science ®Google Scholar
• Armstrong M, Gaunt P, Aithal G, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
   PubMed Web of Science ®Google Scholar
• Newsome P, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113–1124.
   PubMed Web of Science ®Google Scholar
• Aithal G, Thomas J, Kaye P, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–1184.
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison S, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–2307.
   PubMed Web of Science ®Google Scholar
• Bril F, Biernacki D, Kalavalapalli S, et al. Role of Vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–1488.
   PubMed Web of Science ®Google Scholar
• Huang J, Dai C, Huang C, et al. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int. 2021;15(5):1136–1147.
   PubMed Web of Science ®Google Scholar
• Lavine J, Schwimmer J, Van Natta M, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Chalasani N, Kowdley K, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685.
   PubMed Web of Science ®Google Scholar
• Ding C, Tang Y, Zhu W, Ding C, Tang Y, Zhu W, et al. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: a network meta-analysis. Acta Diabetol. 2022;59(4):519–533.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Petracca G, Beatrice G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):2.
   Web of Science ®Google Scholar
• Filipova E, Uzunova K, Kalinov K, et al. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr. 2017;9(1):90.
   PubMedGoogle Scholar
• Panunzi S, Maltese S, Verrastro O, Panunzi S, Maltese S, Verrastro O, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis. Diabetes Obes Metab. 2021;23(4):980–990.
   PubMed Web of Science ®Google Scholar